ABSTRACT
Assessing behavioral change in psychiatric contexts requires retesting patients where, however, ecologically relevant tasks are rarely used. We employed the Ball Search Field Task (BSFT) to evaluate the performance of attention deficit/hyperactivity disorder (ADHD) outpatients before and after administration of methylphenidate (MPH) and compared their performance with that of non-medicated ADHD outpatients and age-matched controls. The outpatient groups showed poorer performance at initial testing, improved performance at re-test although not to the level of the controls, and no clear effect of MPH treatment. The BSFT is thus sufficiently motivating and discriminating for the behavioral evaluation of treatments in psychiatric contexts.
Subject(s)
Attention Deficit Disorder with Hyperactivity/drug therapy , Attention Deficit Disorder with Hyperactivity/psychology , Central Nervous System Stimulants/therapeutic use , Methylphenidate/therapeutic use , Psychomotor Performance/drug effects , Attention/drug effects , Attention/physiology , Central Nervous System Stimulants/pharmacology , Child , Female , Humans , Male , Methylphenidate/pharmacology , Motivation/drug effects , Motivation/physiology , Psychomotor Performance/physiology , Treatment OutcomeABSTRACT
OBJECTIVE: Amoxapine is marketed as an antidepressant. However, its receptor occupancy, in vitro and in vivo, and its effects in pre-clinical models are very similar to atypical antipsychotics. To examine if this leads to an atypical antipsychotic effect in the clinical context, the authors examined the antipsychotic and side-effect profile of amoxapine in acutely psychotic patients with schizophrenia. METHODS: Seventeen patients were enrolled and 15 completed a prospective open-label 6-week study of amoxapine starting with a fixed-starting dose (150 mg/h) with standardized titration up to 250 mg/h, if required. Positive, negative, affective symptoms and side-effects were monitored using standardized weekly assessments. RESULTS: Amoxapine (median final dose 210 mg/h) was well-tolerated and showed significant improvement in positive and negative symptoms (both p<0.001), with a trend towards improvement in mood symptoms and no treatment-emergent extrapyramidal side-effects, akathisia or weight gain. Prolactin elevation was observed. CONCLUSION: These clinical data lend support to the pre-clinical suggestions that amoxapine may be an atypical antipsychotic. Given its lack of weight gain and that it is considerably less expensive than current options, amoxapine could be a valuable alternative for some patients. These considerations strongly call for more systematic, double-blind studies of amoxapine as an atypical antipsychotic.
